Zhejiang Jolly Pharmaceutical Co Ltd Total Liabilities
Zhejiang Jolly Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Zhejiang Jolly Pharmaceutical Co Ltd (300181) has total liabilities worth CN¥1.84 Billion CNY (≈ $268.86 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Zhejiang Jolly Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Zhejiang Jolly Pharmaceutical Co Ltd (2007–2025)
Total liabilities of Zhejiang Jolly Pharmaceutical Co Ltd from 2007 to 2025. This chart illustrates how Zhejiang Jolly Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 300181 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Zhejiang Jolly Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Jolly Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liberty Global PLC Class C
NASDAQ:LBTYK
|
USA | $12.07 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $688.55 Million |
|
Teva Pharmaceutical Industries Ltd
TA:TEVA
|
Israel | ILA32.10 Billion |
|
Kontron AG
VI:KTN
|
Austria | €1.05 Billion |
|
La-Z-Boy Incorporated
NYSE:LZB
|
USA | $1.03 Billion |
|
ATAI Life Sciences NV
XETRA:9VC
|
Germany | €79.91 Million |
|
Guangzhou Restaurants Group Co
SHG:603043
|
China | CN¥3.42 Billion |
|
Inter & Co. Inc. Class A Common Shares
NASDAQ:INTR
|
USA | $88.17 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Zhejiang Jolly Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Zhejiang Jolly Pharmaceutical Co Ltd (300181) total assets.
Liquidity & Leverage Metrics
Zhejiang Jolly Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Zhejiang Jolly Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Jolly Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Jolly Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual total liabilities of Zhejiang Jolly Pharmaceutical Co Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.47 Billion ≈ $215.16 Million |
+25.40% |
| 2024-12-31 | CN¥1.17 Billion ≈ $171.58 Million |
+37.44% |
| 2023-12-31 | CN¥853.09 Million ≈ $124.83 Million |
-2.97% |
| 2022-12-31 | CN¥879.19 Million ≈ $128.65 Million |
+14.88% |
| 2021-12-31 | CN¥765.31 Million ≈ $111.99 Million |
+1.98% |
| 2020-12-31 | CN¥750.43 Million ≈ $109.81 Million |
+16.73% |
| 2019-12-31 | CN¥642.86 Million ≈ $94.07 Million |
-11.51% |
| 2018-12-31 | CN¥726.50 Million ≈ $106.31 Million |
+9.73% |
| 2017-12-31 | CN¥662.06 Million ≈ $96.88 Million |
+16.97% |
| 2016-12-31 | CN¥566.00 Million ≈ $82.82 Million |
+36.40% |
| 2015-12-31 | CN¥414.94 Million ≈ $60.72 Million |
+33.96% |
| 2014-12-31 | CN¥309.75 Million ≈ $45.33 Million |
+82.88% |
| 2013-12-31 | CN¥169.38 Million ≈ $24.79 Million |
+7.02% |
| 2012-12-31 | CN¥158.27 Million ≈ $23.16 Million |
-1.08% |
| 2011-12-31 | CN¥159.99 Million ≈ $23.41 Million |
+13.09% |
| 2010-12-31 | CN¥141.47 Million ≈ $20.70 Million |
+7.12% |
| 2009-12-31 | CN¥132.07 Million ≈ $19.33 Million |
+1.00% |
| 2008-12-31 | CN¥130.76 Million ≈ $19.13 Million |
+22.45% |
| 2007-12-31 | CN¥106.79 Million ≈ $15.63 Million |
-- |
About Zhejiang Jolly Pharmaceutical Co Ltd
Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People's Republic of China and internationally. It offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kid… Read more